跳至主要内容
临床试验/NCT05366595
NCT05366595已完成2 期

Zinc Supplementation in Pediatric Sepsis; a Randomized Controlled Trial

Mansoura University1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2019年7月31日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
72
试验地点
1
主要终点
Mortality rate

研究概览

简要总结

a single blinded randomized controlled clinical trial that was conducted to evaluate the role of zinc supplementation in improving the outcome of infants and children with sepsis in pediatric intensive care unit.

详细描述

a single blinded randomized controlled clinical trial that was conducted to evaluate the role of zinc supplementation in improving the outcome of infants and children with sepsis in pediatric intensive care unit.

The study included 72 cases that were randomly divided into 2 groups

A- Group A (Zinc treated group):

Included 36 cases who received oral zinc sulfate supplementation at doses ranging from 10 mg (infants) to 20 mg (under-five children) of elemental zinc per day, a dosage that is safe in these children.

B- Group B:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
2 Months 至 5 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 2- Pediatric patients who fulfill Pediatric Consensus criteria for definition of severe sepsis as 1) greater than or equal to 2 age-based systemic inflammatory response syndrome criteria, 2) confirmed or suspected invasive infection, and 3) cardiovascular dysfunction, acute respiratory distress syndrome, or greater than or equal to 2 organ system dysfunctions

排除标准

  • Infants and children with history of prematurity (< 37 weeks), chronic cardiopulmonary disease, immunodeficiency, neuromuscular disease, surgical conditions and any other chronic medical condition.
  • Those who are regularly taking vitamin or mineral supplementations

研究组 & 干预措施

Treatment group

Active Comparator

who received oral zinc sulfate supplementation on dose doses ranging from 10 mg (infants) to 20 mg (under-five children) of elemental zinc per day, a dosage that is safe in these children

干预措施: oral zinc sulfate (Drug)

结局指标

主要结局

Mortality rate

时间窗: through study completion an average of one year

Frequency of occurrence of death

次要结局

  • Zinc level(after 10 days of treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Amal Osman

Assistant professor

Mansoura University

研究点 (1)

Loading locations...

相似试验

Zinc Supplementation in Pediatric Sepsis | 临床试验